niacinamide has been researched along with Ascites in 26 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial." | 9.19 | Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014) |
| "The outcomes of sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and impaired liver function remain unresolved." | 7.79 | Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. ( Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM, 2013) |
| "Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)." | 6.79 | TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014) |
| "This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial." | 5.19 | Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014) |
| " In addition, increased hepatic microvasculatures compliance-related improved buffering effect of portal vein to acute mannitol infusion was associated with decreased circulating nitric oxide and aldosterone, plasma volume expansion (dye dilution method), splanchnic blood pooling ((99 m) Tc-RBC SPECT/PET/CT scans), peripheral hypotension, portal hypertension and ascites in brivanib and sorafenib-treated NASH-cirrhotic rats." | 3.80 | Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. ( Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC, 2014) |
| "The outcomes of sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and impaired liver function remain unresolved." | 3.79 | Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. ( Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM, 2013) |
| "Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)." | 2.79 | TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (76.92) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Kilgour, MK | 1 |
| MacPherson, S | 1 |
| Zacharias, LG | 1 |
| Ellis, AE | 1 |
| Sheldon, RD | 1 |
| Liu, EY | 1 |
| Keyes, S | 1 |
| Pauly, B | 1 |
| Carleton, G | 1 |
| Allard, B | 1 |
| Smazynski, J | 1 |
| Williams, KS | 1 |
| Watson, PH | 1 |
| Stagg, J | 1 |
| Nelson, BH | 1 |
| DeBerardinis, RJ | 1 |
| Jones, RG | 1 |
| Hamilton, PT | 1 |
| Lum, JJ | 1 |
| Kim, HY | 1 |
| Park, JW | 1 |
| Joo, J | 1 |
| Kim, H | 1 |
| Woo, SM | 1 |
| Lee, WJ | 1 |
| Kim, CM | 1 |
| Yang, YY | 1 |
| Liu, RS | 1 |
| Lee, PC | 1 |
| Yeh, YC | 1 |
| Huang, YT | 1 |
| Lee, WP | 1 |
| Lee, KC | 1 |
| Hsieh, YC | 1 |
| Lee, FY | 1 |
| Tan, TW | 1 |
| Lin, HC | 1 |
| Legault, G | 1 |
| Kieran, MW | 1 |
| Scott, RM | 1 |
| Chordas, C | 1 |
| Milla, SS | 1 |
| Karajannis, MA | 1 |
| Erhardt, A | 1 |
| Kolligs, F | 1 |
| Dollinger, M | 1 |
| Schott, E | 1 |
| Wege, H | 1 |
| Bitzer, M | 1 |
| Gog, C | 1 |
| Lammert, F | 1 |
| Schuchmann, M | 1 |
| Walter, C | 1 |
| Blondin, D | 1 |
| Ohmann, C | 1 |
| Häussinger, D | 1 |
| HOLZER, H | 5 |
| BOLTZE, HJ | 1 |
| KROEGER, H | 1 |
| ROTTHAUWE, HW | 1 |
| ULRICH, B | 2 |
| HILZ, H | 3 |
| OLDEKOP, M | 2 |
| SCHOLZ, M | 1 |
| FRIEDRICH, G | 1 |
| GRISEBACH, H | 1 |
| HUDACK, ED | 1 |
| EROS, DE | 1 |
| BRUMMOND, DO | 1 |
| FRIEDLAND, IM | 1 |
| FULLER, L | 2 |
| DIETRICH, LS | 3 |
| PRINA, C | 2 |
| MAGRASSI, B | 1 |
| ROVETA, G | 2 |
| AHUJA, JN | 1 |
| WOODS, M | 1 |
| BURK, D | 1 |
| RAIMONDI, L | 1 |
| KOHEN, E | 1 |
| SIEBERT, G | 1 |
| KOHEN, C | 1 |
| KUN, E | 1 |
| LANGER, B | 1 |
| GRUNICKE, H | 1 |
| ALTENBRUNN, HJ | 1 |
| STEENBECK, L | 1 |
| EHRHARDT, E | 1 |
| SCHMAGLOWSKI, S | 1 |
| RUETER, J | 1 |
| WUEPPEN, I | 1 |
| KLEMPIEN, EJ | 1 |
| MIELSCH, M | 1 |
| GRIMBERG, H | 1 |
| DOLD, U | 1 |
| REDETZKI, HM | 1 |
| O'BOURKE, FA | 1 |
| SCHNEIDER, M | 1 |
| Kamat, JP | 1 |
| Devasagayam, TP | 1 |
| Ofori-Nkansah, N | 2 |
| von Bruchhausen, F | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas[NCT01338857] | Phase 2 | 12 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Sorafenib ineffective for tx of recurrent or progressive PLGA) | ||
| Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)[NCT00618384] | Phase 2 | 43 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Determination of tumor response (CR, PR, SD) will be defined based on the comparison of the baseline MRI performed at study entry to the subsequent MRI which demonstrated best response. PR will be defined by a >15% decrease in tumor volume, as measured by 3D volumetric analysis. (NCT01338857)
Timeframe: MRIs performed after every 3rd 28-day cycle and off-study
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar) | 1 |
To estimate the objective response rates to sorafenib in children and young adults with low-grade astrocytomas, including optic pathway gliomas. (NCT01338857)
Timeframe: one year
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar) | 1 |
2 trials available for niacinamide and Ascites
| Article | Year |
|---|---|
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; | 2014 |
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembol | 2014 |
24 other studies available for niacinamide and Ascites
| Article | Year |
|---|---|
1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer.
Topics: Ascites; Female; Humans; Niacinamide; Ovarian Neoplasms; Tumor Microenvironment | 2021 |
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Female; F | 2013 |
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirc | 2014 |
[On the effect of nicotinic acid amide on the inhibition of glycolysis in ascites tumor cells by ethylene imine compounds].
Topics: Amides; Animals; Antineoplastic Agents; Ascites; Carbohydrate Metabolism; Carbohydrates; Carcinoma, | 1961 |
[On the influence of carcinostatic agents on the DPN metabolism of tumors. I. Incorporation of C-14-ribose and C-14-nicotinamide into the DPN of ascites cells].
Topics: Antineoplastic Agents; Ascites; Coenzymes; NAD; Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Rib | 1960 |
Effects of x-ray irradiation in ascites tumor cells: partial restoration of DPN content and DNA synthesis by nicotinamide.
Topics: Animals; Ascites; Coenzymes; DNA; DNA Replication; NAD; Neoplasms, Experimental; Niacin; Niacinamide | 1961 |
[Evaluation of nicotinic acid and nicotinamide for the biosynthesis of DPN in ascites tumor cells].
Topics: Ascites; Coenzymes; NAD; Neoplasms; Niacin; Niacinamide; Nicotinic Acids | 1961 |
Studies on Ehrlich ascites cell nuclei. IV. Determination of nicotinamide adenosine dinucleotide pyrophosphorylase activity in nuclei isolated by an improved technique.
Topics: Adenosine; Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; Cell Nucleus; NAD; Niacinamide; Ph | 1963 |
Nicotinic acid and nicotinamide metabolism in ascites cells in vitro.
Topics: Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; In Vitro Techniques; NAD; Niacin; Niacinamide | 1962 |
[Complexes of 3,4-benzopyrene and various substances in aqueous solution. Action in vitro and in vivo on Ehrlich's ascites cancer cells].
Topics: Animals; Ascites; Benzo(a)pyrene; Benzopyrenes; Caffeine; Carcinoma; Carcinoma, Ehrlich Tumor; Hista | 1962 |
Uptake of nicotinic acid-C-14 and nicotinamide-C-14 by ascites cells in vitro.
Topics: Ascites; In Vitro Techniques; NAD; Neoplasms; Neoplasms, Experimental; Niacin; Niacinamide; Nicotini | 1963 |
FORMATION OF GLYCOLYTIC INHIBITOR FROM 6-AMINONICOTINAMIDE BY ASCITES TUMOR CELLS IN VIVO AND IN VITRO, AND METABOLIC REQUIREMENTS FOR FORMATION OF THIS INHIBITOR.
Topics: 6-Aminonicotinamide; Animals; Ascites; Carbohydrate Metabolism; Carcinoma, Ehrlich Tumor; Enzyme Inh | 1963 |
[ACTION OF WATER-SOLUBLE COMPLEXES OF 3,4-BENZOPYRENE ON TUMOR ASCITES FLUIDS. ELECTROPHORETIC STUDIES].
Topics: Animals; Ascites; Benzo(a)pyrene; Benzopyrenes; Carbohydrates; Carcinoma, Ehrlich Tumor; Electrophor | 1963 |
METABOLISM OF REDUCED PYRIDINE NUCLEOTIDES IN ASCITES CELL NUCLEI.
Topics: Amobarbital; Ascites; Cell Nucleus; Citrates; Fluorescence; Fluorometry; Glucose; Histocytochemistry | 1964 |
NICOTINAMIDE ADENINE DINUCLEOTIDE SYNTHESIS IN ASCITES CELLS IN VITRO.
Topics: Ascites; Carbon Isotopes; Chromatography; Glucose; Glutamine; In Vitro Techniques; Metabolism; Mice; | 1964 |
THE ROLE OF DPNASE IN THE MECHANISM OF ACTION OF AN ANTITUMOR ALKYLATING AGENT ON EHRLICH ASCITES CELLS.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Ascites; Carbohydrate Metabolism; Carcinoma; Carc | 1964 |
[INVESTIGATION ON THE DECREASE IN CONCENTRATION OF NAD IN LYMPHOSARCOMA ASCITES CELLS FOLLOWING X-IRRADIATION].
Topics: Ascites; Chromatography; Lymphoma; Lymphoma, Non-Hodgkin; Metabolism; NAD; Neoplasms; Neoplasms, Exp | 1965 |
STIMULATION OF DPN TURNOVER IN ASCITES TUMOR CELLS BY LOW X-RAY DOSES.
Topics: Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; DNA; DNA, Neoplasm; Metabolism; N-Glycosyl Hy | 1965 |
[On the effect of cytostatic compounds and nicotinic acid amide on ascites tumor ribonuclease (n)].
Topics: Amides; Animals; Antineoplastic Agents; Ascites; Carcinoma, Ehrlich Tumor; Humans; Neoplasms, Experi | 1959 |
[Influence of nicotinamide on the DPN-content, glycolysis and viability of ascites tumor cells after treatment with carcinostatic ethyleneimine compounds].
Topics: Animals; Antineoplastic Agents; Ascites; Aziridines; Coenzymes; Glycolysis; Humans; NAD; Neoplasms, | 1962 |
Influence of nicotic acid and nicotinamide on diphosphopyridine nucleotide (DPN) Synthesis in ascites tumor cells.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Coenzymes; NAD; Neoplasms; Niacin; Niacinamide; Nicotini | 1961 |
Oxidative damage to mitochondria in normal and cancer tissues, and its modulation.
Topics: Animals; Antioxidants; Ascites; Brain; Caffeine; Gamma Rays; Male; Mitochondria, Liver; Niacinamide; | 2000 |
Metabolic alterations in Yoshida ascites tumour cells caused by 6-aminonicotinamide and prevented by nicotinamide.
Topics: Amines; Animals; Ascites; Carbon Dioxide; Carbon Isotopes; Fructosephosphates; Gluconates; Glucose; | 1972 |
Some metabolic and morphological alterations in Yoshida ascites tumour cells caused by 6-aminonicotinamide.
Topics: Animals; Ascites; Cell Nucleus; Endoplasmic Reticulum; Fructosephosphates; Gluconates; Glucose-6-Pho | 1972 |